1. Sunder TR. Meeting the challenge of epilepsy in persons with multiple handicaps. J Child Neurol 1997;12[Suppl 1]:S38–S43.

2. Lund J. Epilepsy and psychiatric disorder in the mentally retarded adult. Acta Psychiatr Scand 1985;72:557–562.

3. Coulter DL. Comprehensive management of epilepsy in persons with mental retardation. Epilepsia 1997;38[Suppl 4]:S24–S31.

4. Rivinus TM. Psychiatric effects of the anticonvulsant regimens. J Clin Psychopharmacol 1982;2:165–192.

5. Ketter TA, Post RM, Theodore WH. Positive and negative psychotropic effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53[Suppl 1]:S52–S66.

6. Aman MG, Singh NN. Aberrant Behavior Checklist. East Aurora, NY: Slosson Educational Publications, 1994.

7. Sturmey P, Carlsen A, Crisp AG, Newton JT. A functional analysis of multiple aberrant responses: a refinement and extension of Iwata et al.'s (1982) methodology. J Ment Defic Res 1988;32:31–46.

8. Iwata BA, Wong SE, Riordan MM, et al. Assessment and training of clinical interviewing skills: analogue analysis and field replication. J Appl Behav Anal 1982;15:191–203.

9. Einfeld SL. Guidelines for the use of psychotropic medication in individuals with developmental disabilities. Aust N Z J Dev Disabil 1990;16:71–73.

10. Kalachnik JE, Hanzel TE, Harder SR, et al. Antiepileptic drug behavioral side effects in individuals with mental retardation and the use of behavioral measurement techniques. Ment Retard 1995;33:374–382.

11. Bates ER, Wilder BJ, Brown R, et al. Antiepileptic drug reduction program at a center for the developmentally disabled (abstract). Epilepsia 1991;32[Suppl 3]:3.

12. Schmidt D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia 1983;24:368–376.

13. Bennet HS, Dunlop T, Ziring PR. Reduction of polypharmacy for epilepsy in an institution for the retarded. Dev Med Child Neurol 1983;25:735–737.

14. Devinsky O. Cognitive and Behavioral Effects of AEDs. Annual Course of the American Epilepsy Society: New Developments in Antiepileptic Drug Therapy. New Orleans: American Epilepsy Society, 1994;E1–E50.

15. Bourgeois BFD. Antiepileptic drugs, learning, and behavior in childhood epilepsy. Epilepsia 1998;39:913–921.

16. Ettinger AB, Weisbrot DM, Krupp LB, et al. Fatigue and depression in epilepsy. J Epilepsy 1998;11:105–109. 1997;1475–1489.

17. Ko DY, Rho JM, DeGiorgio CM, Sato S. Benzodiazepines. In JJ Engel, TA Pedley (eds), Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven, 1997;1475–1489.

18. Rickels K, Chung HR, Csanalosi IB, et al. Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. Arch Gen Psychiatry 1987;44:862–866.

19. Bradwejn J, Shriqui C, Koszycki D, Meterissian G. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol 1990;10:403–408.

20. Farrell K. Symptomatic generalized epilepsy and Lennox-Gastaut syndrome. In E Wyllie (ed), The Treatment of Epilepsy (2nd ed). Baltimore: Williams & Wilkins, 1996;530–539.

21. Schoch P, Moreau JL, Martin JR, Haefely WE. Aspects of benzodiazepine receptor structure and function with relevance to drug tolerance and dependence. Biochem Soc Symp 1993;59:121–134.

22. Bittencourt PRM, Richens A. Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia 1981;22:129–134.

23. Prior PF, Maclaine GN, Scot DF, Laurance BM. Tonic status epilepticus precipitated by intravenous diazepam in a child with petit mal status. Epilepsia 1982;13:467–472.

24. Bawden HN, Camfield CS, Camfield PR, et al. The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Epilepsy Res 1999;33:133–143.

25. Hauser P, Devinsky O, DeBellis M, et al. Benzodiazepine withdrawal delirium with catatonic features. Arch Neurol 1989;46:696–699.

26. Meador KJ, Loring DW, Moore EE, et al. Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults. Neurology 1995;45:1494–1499.

27. Stoudemire A, Fogel BS. Psychiatric Care of the Medical Patient. New York: Oxford University Press, 1993;475–476.

28. Poindexter AR, Berglund JA, Kolstoe PD. Changes in antiepileptic drug prescribing patterns in large institutions: preliminary results of a five-year experience. Am J Ment Retard 1993;98:34–40.

29. Rickels K, Pereira-Ogan JA, Chung HR, et al. Bromazepam and phenobarbital in anxiety: a controlled study. Curr Ther Res Clin Exp 1973;15:679–690.

30. Schaffer LC, Schaffer CB, Caretto J. The use of primidone in treatment of refractory bipolar disorder. Ann Clin Psychiatry 1999;11:61–66.

31. Robertson MM. Depression in patients with epilepsy: an overview and clinical study. In MR Trimble (ed), The Psychopharmacology of Epilepsy. Chichester, UK: Wiley, 1985.

32. Brent DA, Crumrine PK, Varma R, et al. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987;80:909–917.

33. Perrine K, Congett S. Neurobehavioral problems in epilepsy. Neurol Clin 1994;12:129–152.

34. Ounsted C. The hyperkinetic syndrome in epileptic children. Lancet 1955;2:203.

35. Wolf S, Forsythe A. Behavioral disturbance, phenobarbital and febrile seizures. Pediatrics 1978;61:728–731.

36. Thorn I. A controlled study of prophylactic long-term treatment of febrile convulsions with phenobarbital. Acta Neurol Scand 1975;60[Suppl]:67–73.

37. Corbett JA, Trimble MR, Nichol TC. Behavioral and cognitive impairments in children with epilepsy: the long-term effects of anticonvulsant therapy. J Am Acad Child Psychiatry 1985;24:17–23.

38. Camfield C, Chaplin S, Doyle AB, et al. Side effects of phenobarbital in toddlers: behavioral and cognitive aspects. J Pediatr 1979;95:361–365.

39. Ferrari M, Barabas G, Matthews W. Psychologic and behavioral disturbance among epileptic children treated with barbiturate anticonvulsants. Am J Psychiatry 1983;140:112–113.

40. Wilder BJ. Phenytoin: Clinical use. In RH Levy, RH Mattson, BS Meldrum (eds), Antiepileptic Drugs (4th ed). New York: Raven Press, 1995;334–344.

41. Weisbrot DM, Ettinger AB. Epilepsy and behavior: controversies and caveats. Neurologist 1997;3:155–172.

42. Dam M. Phenytoin: toxicity. In DM Woodbury, JK Penry, CE Pippenger (eds), Antiepileptic Drugs. New York: Raven Press, 1982;247–256.

43. Dodrill CB, Troupin AS. Neuropsychological effects of carbamazepine and phenytoin: a reanalysis. Neurology 1991;41:141–143.

44. Meador KJ, Loring DW, Allen ME, et al. Comparative cognitive effects of carbamazepine and phenytoin in healthy adults. Neurology 1991;41:1537–1540.

45. Landolt H. Serial electroencephalographic investigations during psychotic episodes in epileptic patients and during schizophrenic attacks. In L deHass (ed), Lectures on Epilepsy. London: Elsevier, 1958.

46. Wolf P. Acute behavioral symptomatology at disappearance of epileptiform EEG abnormality: paradoxical or "forced" normalization. In D Smith, D Treiman, M Trimble (eds), Neurobehavioral Problems in Epilepsy. Advances in Neurology. New York: Raven Press, 1991;127–142.

47. Delgado-Escueta AV, Treiman DM, Walsh GO. The treatable epilepsies. N Engl J Med 1983;308:1508–1514.

48. Deb S, Joyce J. The use of antiepileptic medication in a population-based cohort of adults with learning disability and epilepsy. Int J Psychiatry Clin Pract 1999;3:129–133.

49. Small JG, Klapper MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991;48:915–921.

50. Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992;149:108–111.

51. Post RM, Ketter TA, Denicoff K, et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology 1996;128:115–129.

52. Stoll AL, Banov M, Kolbrener M, et al. Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994;14:311–313.

53. Kastner T, Finesmith R, Walsh K. Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation. J Clin Psychopharmacol 1993;13:448–451.

54. Gupta S, O'Connell RO, Parekh A, et al. Efficacy of valproate for agitation and aggression in dementia: case reports. Int J Geriatr Psychopharmacol 1998;1:244–248.

55. Knowles SR. Adverse effects of antiepileptics. Can J Clin Pharmacol 1999;6:137–148.

56.Prevey ML, Delaney RC, Cramer JA, et al. Effect of valproate on cognitive functioning: comparison with carbamazepine. Arch Neurol 1996;53:1008–1016.

57. Duncan JS, Shorvon SD, Trimble MR. Effects of removal of phenytoin, carbamazepine, and valproate on cognitive function. Epilepsia 1990;31:584–591.

58. Zaret BS, Cohen RA. Reversible valproic acid–induced dementia: a case report. Epilepsia 1986;27:234–240.

59. Marescaux C, Warter JM, Micheletti G, et al. Stuporous episodes during treatment with sodium valproate: report of seven cases. Epilepsia 1982;23:297–305.

60. Husain SB, Wical BS. Adverse behavioral effects of valproate therapy in children with complex partial seizures (abstract). Epilepsia 1998;39[Suppl 6]:162.

61. Friedman DL, Kastner T, Plummer AT. Adverse behavioral effects in individuals with mental retardation and mood disorders treated with carbamazepine. Am J Ment Retard 1992;96:541–546.

62. Reid AH, Naylor GJ, Kay DS. A double-blind placebo-controlled crossover trial of carbamazepine in overactive severely mentally handicapped patients. Psychol Med 1981;11:109–113.

63. Silver JM, Yudofsky SC, Hurowitz GI. Psychopharmacology and electroconvulsive therapy. In RE Hales, SC Yudofsky, JA Talbott (eds), Textbook of Psychiatry (2nd ed). Washington, DC: American Psychiatric Press, 1994;897–1007.

64. Snead OC. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985;313:916–921.

65. Shields WD, Saslow E. Myoclonic, atonic and absence seizures following institution of carbamazepine therapy in children. Neurology 1983;33:1487–1489.

66. Ojemann LM, Wilensky AJ, Temkin NR, et al. Long- term treatment with gabapentin for partial epilepsy. Epilepsy Res 1992;13:159–165.

67. Dimond KR, Pande AC, Lamoreaux L, Pierce MW. Effect of gabapentin (Neurontin) on mood and well-being in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:407–417.

68. Harden C, Pick L. Alterations in mood and anxiety in epilepsy patients treated with gabapentin (abstract). Epilepsia 1996;37[Suppl 5]:137.

69. Brodie MJ, Richens A, Yuen A. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:468–476.

70. Handforth A, Treiman DM. Efficacy and tolerance of long-term, high-dose gabapentin: additional observations. Epilepsia 1994;35:1032–1037.

71. Harden CL, Lazar LM, Pick LH, et al. A beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia 1999;40:1129-1134.

72. Dodrill CB, Arnett JL, Hayes AG, et al. Cognitive abilities and adjustment with gabapentin: results of a multisite study. Epilepsy Res 1999;35:109–121.

73. Mortimore C, Trimble M, Emmers E. Effects of gabapentin on cognition and quality of life in patients with epilepsy. Seizure 1998;7:359–364.

74. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999;52:321–327.

75. McElroy SL, Soutullo CA, Keck PE, Kmetz GF. A pilot trial of adjunctive gabapentin in the treatment of bipolar disease. Ann Clin Psychiatry 1997;6:99–103.

76. Ryback RS, Brodsky L, Manasifi F. Gabapentin in bipolar disorder (letter). J Neuropsychiatry Clin Neurosci 1997;9:301.

77. Knoll J, Stegman K, Suppes T. Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania. J Affect Disorder 1998;49:229–233.

78. Schaffer CB, Schaffer LC. Gabapentin in the treatment of bipolar disorder. Am J Psychiatry 1997;154:291–292.

79. Young LT, Robb JC, Patelis-Siotis I, et al. Acute treatment of bipolar depression with gabapentin. Biol Psychiatry 1997;42:851–853.

80. Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK. Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry 1997;59:426–429.

81. Ryback R, Ryback L. Gabapentin for behavioral dyscontrol (letter). Am J Psychiatry 1995;152:1399.

82. Sheldon LJ, Ancill RJ, Holliday SG. Gabapentin in geriatric psychiatry patients. Can J Psychiatry 1998;43:422–423.

83. Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders (letter). Am J Psychiatry 1998;155:992.

84. Pande AC, Davidson JRT, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo controlled study. J Psychopharmacol 1999;19:341–348.

85. McManaman J, Tam DA. Gabapentin for self-injurious behavior in Lesch-Nyhan syndrome. Pediatr Neurol 1999;20:381–382.

86. Wolf SM, Shinnar S, Kang H, et al. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1995;36:1203–1205.

87. Lee DO, Steingard RJ, Cesena M, et al. Behavioral side effects of gabapentin in children. Epilepsia 1996;37:87–90.

88. Motte J, Trevathan E, Arvidsson JFV, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1997;337:1807–1812.

89. Beran RG, Gibson RJ. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 1998;39:280–282.

90. Ettinger AB, Weisbrot DM, Saracco J, et al. Positive and negative psychotropic effects of lamotrigine in epilepsy patients with mental retardation. Epilepsia 1998;39:874–877.

91. Kotler M, Matar MA. Lamotrigine in the treatment of resistant bipolar disorder. Clin Neuropharmacol 1998;21:65–67.

92. Calabrese JR, Fatemi SH, Woyshville MJ. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder (letter). Am J Psychiatry 1996;153:1236.

93. Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatr Res 1997;72:145–148.

94. Smith D, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312–322.

95. Meador KJ, Baker GA. Behavioral and cognitive effects of lamotrigine. J Child Neurol 1997;12:S44–S47.

96. Besag FMC. Lamotrigine in the management of subtle seizures. Rev Contemp Pharmacother 1994;5:123–131.

97. Rowan AJ, Uthman B, Ahmann P, et al. Safety and efficacy of three dose levels of tiagabine HCl versus placebo as adjunctive treatment for complex partial seizures. Epilepsia 1994;35[Suppl 8]:54.

98. Dodrill CB, Arnett JL, Shu V, et al. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998;39:33–42.

99. Kaufman KR. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry 1998;10:181–184.

100. Leppik IE. Tiagabine: the safety landscape. Epilepsia 1995;36:S10–S13.

101. Ettinger AB, Bernal OG, Andriola MR, et al. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy. Epilepsia 1999;40:1159–1162.

102. Brodie MJ. Tiagabine in the management of epilepsy. Epilepsia 1997;38:S23–S27.

103. Dodrill CB, Arnett JL, Sommerville KW. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997;48:1025–1031.

104. Sveinbjornsdottir S, Sander JWAS, Patsalos PN, et al. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994;3:29–35.

105. Sander JWAS, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 1991;54:435–439.

106. Dulac O, Chiron C, Luna D, et al. Vigabatrin in childhood epilepsy. J Child Neurol 1991;6:2S30–2S37.

107. Appelton R. The role of vigabatrin in the management of infantile epileptic syndromes. Neurology 1993;43:S21–S23.

108. Ben-Menachem E, French J. Vigabatrin. In J Engel, TA Pedley (eds), Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven, 1997;1609–1618.

109. Macleod AD. Vigabatrin and posttraumatic stress disorder. J Clin Psychopharmacol 1996;16:190–191.

110. Eske T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;314:180–181.

111. Ketter TA, Malow BA, Flamini R, et al. Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res 1996;23:129–137.

112. Asconape JJ, Brotherton TA, Lauve LM, et al. Felbamate: efficacy and tolerability in patients with refractory epilepsies (abstract). Epilepsia 1994;35[Suppl 8]:114.

113. Ettinger AB, Jandorf L, Berdia A, et al. Felbamate- induced headache. Epilepsia 1996;37:503–505.

114. King JA. Increased incidence of adverse behavioral side effects associated with the addition of felbamate (FBM) to antiepileptic drug (AED) regimens in the mentally retarded (MR) population (abstract). Epilepsia 1994;35[Suppl 8]:94.

115. Woodhams KA, Bennett B, Bronstein KS, et al. Behavioral changes in individuals treated with felbamate (abstract). Epilepsia 1994;35[Suppl 8]:160.

116. Crawford P. An audit of topiramate use in a general neurology clinic. Seizure 1998;7:207–211.

117. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52:1330–1337.

118. Faught E, French J, Harden C. Postmarketing Antiepileptic Drug Survey Group (PADS). Adverse effects of TPM: results from a large post-marketing survey (abstract). Epilepsia 1997;38[Suppl 8]:97.

119. Faught E, Kuzniecky R, Gilliam F. Cognitive effects of TPM (abstract). Neurology 1997;48:A336.

120. Sachdeo RC, Glauser TA, Ritter F, et al. A double- blind, randomized trial of topiramate in Lennox-Gas- taut syndrome. Neurology 1999;52:1882–1887.

121. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37[Suppl 2]:S18–S22.

122. Tassanari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763–768.

123. Abou-Khalil B, Fakhoury T. Neuropsychiatric profile of high-dose topiramate (abstract). Epilepsia 1997;38[Suppl 8]:207.

124. Betts T, Smith K, Khan G. Severe psychiatric reactions to topiramate (abstract). Epilepsia 1997;38[Suppl 3]:64.

125. Dohmeier C, Kay A, Greathouse N. Neuropsychiatric complications of topiramate therapy (abstract). Epilepsia 1998;39[Suppl 6]:189.

126. Marcotte TD. Topiramate in the Treatment of Mood Disorders (abstract 115). Presented at the one hundred fifty-first annual meeting of the American Psychiatric Association. Toronto, Ontario, Canada, May 30–June 4, 1998.

127. Calabrese JR, Shelton MD III, Keck PE Jr, et al. Pilot study of topiramate in acute severe treatment-refractory mania. Presented at the one hundred fifty-first annual meeting of the American Psychiatric Association. Toronto, Ontario, Canada, May 30–June 4, 1998.

128. Suppes T, Brown ES, McElroy SL, et al. A pilot trial of adjunctive topiramate in the treatment of bipolar disorder: application of the Stanley Foundation Bipolar Network (SFBN) prospective protocol (abstract). Proceedings of the Thirty-Seventh Annual Meeting of the American College of Neuropsychopharmacology. Las Croabas, Puerto Rico, 1998;306.

129. Sherman C. Topiramate may curb bingeing in bipolar patients. Clin Psychiatry News 1999;27:4.

130. Curry WJ, Kulling DL. Newer antiepileptic drugs: gabapentin, lamotrigine, felbamate, topiramate and fosphenytoin. Am Fam Physician 1998;57:513–520.

131. Reid SA. Surgical technique for implantation of the neurocybernetic prosthesis. Epilepsia 1990;31[Suppl 2]:S38–S39.

132. Walker BR, Easton A, Gale K. Regulation of limbic motor seizures by GABA and glutamate transmission in nucleus tractus solitarius. Epilepsia 1999;40:1051–1057.

133. Ben-Menachem E, Hellstrom K, Waldton C, Augustinsson LE. Evaluation of refractory epilepsy treated with vagus nerve stimulation for up to 5 years. Neurology 1999;52:1265–1267.

134. Helmers SL, Al-Jayyousi M, Madsen J. Adjunctive treatment in Lennox-Gastaut syndrome using vagal nerve stimulation (abstract). Epilepsia 1998;39[Suppl 6]:169.

135. Parker APJ, Polkey CE. Vagal nerve stimulation in epileptic encephalopathies. Pediatrics 1999;103:778–782.

136. Clark KB, Krahl SE, Smith DC, Jensen RA. Post- training unilateral vagal stimulation enhances retention performance in the rat. Neurobiol Learn Mem 1995;63:213–216.

137. Clark KB, Naritoku DK, Smith DC, et al. Enhanced recognition memory following vagus nerve stimulation in human subjects. Nature Neurosci 1999;2:94–98.

138. Harden CL, Pulver MC, Nikolov B, et al. Effects of vagus nerve stimulation on mood in adult epilepsy patients (abstract). Neurology 1999;52[Suppl 2]:A238.

139. Ettinger AB, Nolan E, Vitale S, et al. Changes in mood and quality of life in adult epilepsy patients treated with vagal nerve stimulation (abstract). Epilepsia 1999;40:62.

From: Ettinger AB, Barr WB, and Solomon SP. Psychotropic properties of antiepileptic drugs in patients with developmental disabilities. In: Devinsky O and Westbrook LE, eds. Epilepsy and Developmental Disabilities. Boston: Butterworth-Heinemann; 2001;219–230. With permission from Elsevier (www.elsevier.com).

Authored By: 
Sanford P. Solomon MD
William B. Barr MD
Alan B. Ettinger MD
I<
Reviewed By: 
Steven C. Schachter MD
on: 
Wednesday, March 31, 2004